14.02.2019

In 2018, Petrovax Pharm continued exports to the EAEU, EU, and Iran. As of 2018, exports amounted to about 1B RUB accounting for 11.8% in the company’s total sales.

We intend to continue growing our geographic expansion. In this respect, we are traditionally bound for two destinations: first, for building up our presence in the existing markets, i.e. the EAEU, Iran, and the European Union, in particular, Slovakia; second, for opening new markets; the company is getting ready to enter Egypt’s market
Mikhail Tsyferov, Petrovax Pharm CEO

Currently, Petrovax Pharm supplies Grippol® plus vaccine to six countries (Belarus, Kazakhstan, Iran, Kyrgyzstan, Turkmenistan, and Uzbekistan) under the state-funded free vaccination programs. Over the past 3 years (2016–2018), Petrovax Pharm’s exports of the influenza vaccine for free immunization of the population exceeded 18M shots.

The market launch of Grippol® Quadrivalent vaccine provides for new opportunities in developing the company’s exports.

Quite naturally, in all foreign markets where we operate, the trivalent vaccine will be gradually substituted with the more advanced quadrivalent vaccine. We intend to build up our presence in Iran. Hopefully, we will be issued a marketing authorization for Grippol® Quadrivalent in 2019 and will start exporting the vaccine to that country
Mikhail Tsyferov, Petrovax Pharm CEO

Presently, Petrovax Pharm is the first and only Russian pharmaceutical manufacturer to supply an influenza vaccine to Iran. Since 2016, 1,35M shots of trivalent flu vaccine Grippol® plus were exported to Iran.

Polyoxidonium® is among the company’s successfully exported pharmaceutical products.

We have been fairly successful selling in Slovakia as well as other EAEU countries. There are long-term plans for expanding not only our product range but also geographic footprint in the European Union. Our company has been built around Polyoxidonium molecule that, in essence, has made a platform for our vaccines and other pharmaceuticals. We believe that this powerful platform’s potential has not been exhausted yet. Therefore, we will further develop Polyoxidonium’s innovative properties. We purposefully extend the range of our clinical studies to provide for a higher quality evidence base and comply with the most stringent international guidelines.
Mikhail Tsyferov, Petrovax Pharm CEO

Thus, in 2017, the company was issued a positive Post-Authorisation Safety Study (PASS) report for Polyoxidonium® in the EU (Slovakia); Petrovax initiated this study in 2016. The PASS has confirmed a high safety profile and good tolerability of Polyoxidonium® among the patients.

Petrovax Pharm also has long-standing partnership relations with Ukraine. Since 2004, the company has supplied Polyoxidonium® and Longidaze® to the Ukrainian market. In 2012, Petrovax was issued an EU GMP certificate for its manufacturing and Quality Management System by Ukraine’s state regulator.

We continue operating in the Ukrainian market.. To date, Polyoxidonium® and Longidaze® injections have been authorised in Ukraine. Re-authorisation is underway for two Polyoxidonium® dosage forms, i.e. vaginal and rectal suppositories 12 mg and tablets 12 mg. In 2017–2018, more than 5,000 packs of Longidaze® and more than 9,000 packs of Polyoxidonium® were supplied to Ukraine. We plan to further supply our pharmaceutical products to and develop partnerships within that country
Olga Orekhova, Petrovax Pharm’s Vice President, R&D and Regulatory Affairs, Russia and Foreign Markets

Petrovax Pharm’s export business has been running since 2002. Today, the company exports to 12 countries including Belarus, Kazakhstan, Kyrgyzstan, Ukraine, Turkmenistan, Azerbaijan, Moldova, Armenia, Georgia, Uzbekistan, Slovakia, and Iran. The exported products include Grippol® plus, Polyoxidonium®, Longidaze®, and Imoferaza®. Belarus, Kazakhstan, and Uzbekistan account for the highest percentage in the company’s export structure. The company has an apparent competitive edge for export activities, i.e. a branded product portfolio, state-of-the-art high-tech manufacturing facilities complying with the applicable international GMPs, and an investment-based development strategy.


Back to the list